PIM1 and acute myeloid leukemia: AZD1208 is a potent, ATP-competitive, pan-PIM kinase inhibitor designed to target PIM1, 2 and 3.11 It has been investigated in preclinical models of AML and prostate cancer.12,13 In AML cell lines, inhibition of cell growth by AZD1208 correlated with PIM1 expression.